The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background and Aim
The multi‐kinase inhibitor regorafenib (REG) was recently demonstrated to be effective in patients with sorafenib (SOR)‐resistant hepatocellular carcinoma (HCC). Interestingly, SOR is known to enhance the accumulation of membrane‐bound MHC class I polypeptide‐related sequence A (mMICA) in HCC cells and to block the production of soluble MICA (sMICA), an immunological decoy. In...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.